FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051258608> ?p ?o ?g. }

• W2051258608 endingPage "276" @default.
• W2051258608 startingPage "268" @default.
• W2051258608 abstract "Immunosuppression therapy in lung transplantation (LTX) remains unsatisfactory due to a high incidence of infection and frequent acute rejection (AR), leading to early onset of the bronchiolitis obliterans syndrome (BOS). The long-term success of LTX is limited by BOS, associated with marked morbidity and mortality. The strongest risk factor for BOS is frequent AR. Decreasing frequent AR episodes might lead to improved long-term survival following LTX.Despite the introduction of many novel agents, the basis of currently applied protocols remains a calcineurin inhibitor, that is, cyclosporine/tacrolimus (TAC). Eighty-two lung recipients received oral-only administered immunosuppression with oral TAC, mycophenolate mofetil (MMF) and intravenous (IV) methylprednisolone as introduction 2h prior to skin incision. Intra-operatively, patients received additional methylprednisolone prior to unclamping the pulmonary arteries. Postoperatively oral TAC/MMF and prednisolone were continued and trough levels closely monitored (target 8-12 ng ml(-1)). Pulmonary function tests were performed frequently and daily after discharge by means of a self-measuring device (daily forced expiratory volume in 1s (FEV(1))) as the major part of a close follow-up and monitoring programme. Trans-bronchial biopsies were rarely performed. Patient data were collected prospectively and stored in transplantation registries. LTX survival was analysed according to the Kaplan-Meier method.The follow-up of the LTX patients through frequent ambulatory care unit visits and close monitoring of the immunosuppressive regimen and the medication response was 100% complete. The mean duration of observation per patient was 1.8 + or - 1.7 years (median 1.4, range: 0.0-6.4 years) and this study included 176.5 patient-related years of follow-up. The 1-, 3- and 5-year survival following LTX was 70%, 60% and 55%, respectively. Eight patients (10%) underwent high-dose intravenous (IV) bolus methylprednisolone treatment and taper for AR. Two additional patients developed BOS more than 4 years following LTX. The AR- and BOS-related mortality was 0% within the 7-year interval of LTX. Alterations in FEV(1) were associated with significant anastomotic airway and infectious complications, requiring frequent bronchoscopic interventions, stenting and laser therapy as well as frequent IV antibiotic treatment. The 30-day and in-hospital mortality of 19.5% was markedly related to primary graft failure and viral infection. Long-term survival was limited predominantly by cytomegalovirus (CMV) infection and sepsis.Our results suggest that a standard immunosuppressive regimen of TAC and MMF orally administered and introduced prior to skin incision for LTX surgery and maintained long-term might reduce the incidence of acute and chronic rejection. Viral infections and not BOS seemed to be the limiting factor of long-term survival." @default.
• W2051258608 created "2016-06-24" @default.
• W2051258608 creator A5015898233 @default.
• W2051258608 creator A5027502266 @default.
• W2051258608 creator A5028247097 @default.
• W2051258608 creator A5033250422 @default.
• W2051258608 creator A5035268766 @default.
• W2051258608 creator A5044788619 @default.
• W2051258608 creator A5058190750 @default.
• W2051258608 creator A5062277288 @default.
• W2051258608 date "2010-09-01" @default.
• W2051258608 modified "2023-10-03" @default.
• W2051258608 title "Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation☆" @default.
• W2051258608 cites W1411210768 @default.
• W2051258608 cites W1964657725 @default.
• W2051258608 cites W1966974215 @default.
• W2051258608 cites W1978364729 @default.
• W2051258608 cites W1997098181 @default.
• W2051258608 cites W1998379866 @default.
• W2051258608 cites W2014491818 @default.
• W2051258608 cites W2016950388 @default.
• W2051258608 cites W2017689505 @default.
• W2051258608 cites W2019639749 @default.
• W2051258608 cites W2027497658 @default.
• W2051258608 cites W2040767465 @default.
• W2051258608 cites W2051089409 @default.
• W2051258608 cites W2058890948 @default.
• W2051258608 cites W2072305618 @default.
• W2051258608 cites W2096933858 @default.
• W2051258608 cites W2106498774 @default.
• W2051258608 cites W2132227824 @default.
• W2051258608 cites W2139168505 @default.
• W2051258608 cites W2144391693 @default.
• W2051258608 cites W2411290906 @default.
• W2051258608 cites W2766892013 @default.
• W2051258608 cites W332448539 @default.
• W2051258608 doi "https://doi.org/10.1016/j.ejcts.2010.01.066" @default.
• W2051258608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20304665" @default.
• W2051258608 hasPublicationYear "2010" @default.
• W2051258608 type Work @default.
• W2051258608 sameAs 2051258608 @default.
• W2051258608 citedByCount "9" @default.
• W2051258608 countsByYear W20512586082012 @default.
• W2051258608 countsByYear W20512586082014 @default.
• W2051258608 countsByYear W20512586082022 @default.
• W2051258608 crossrefType "journal-article" @default.
• W2051258608 hasAuthorship W2051258608A5015898233 @default.
• W2051258608 hasAuthorship W2051258608A5027502266 @default.
• W2051258608 hasAuthorship W2051258608A5028247097 @default.
• W2051258608 hasAuthorship W2051258608A5033250422 @default.
• W2051258608 hasAuthorship W2051258608A5035268766 @default.
• W2051258608 hasAuthorship W2051258608A5044788619 @default.
• W2051258608 hasAuthorship W2051258608A5058190750 @default.
• W2051258608 hasAuthorship W2051258608A5062277288 @default.
• W2051258608 hasBestOaLocation W20512586081 @default.
• W2051258608 hasConcept C126322002 @default.
• W2051258608 hasConcept C128057223 @default.
• W2051258608 hasConcept C141071460 @default.
• W2051258608 hasConcept C2776715498 @default.
• W2051258608 hasConcept C2776739411 @default.
• W2051258608 hasConcept C2779609443 @default.
• W2051258608 hasConcept C2780252810 @default.
• W2051258608 hasConcept C2780372218 @default.
• W2051258608 hasConcept C2781413609 @default.
• W2051258608 hasConcept C2781448352 @default.
• W2051258608 hasConcept C2909675724 @default.
• W2051258608 hasConcept C2911091166 @default.
• W2051258608 hasConcept C71924100 @default.
• W2051258608 hasConceptScore W2051258608C126322002 @default.
• W2051258608 hasConceptScore W2051258608C128057223 @default.
• W2051258608 hasConceptScore W2051258608C141071460 @default.
• W2051258608 hasConceptScore W2051258608C2776715498 @default.
• W2051258608 hasConceptScore W2051258608C2776739411 @default.
• W2051258608 hasConceptScore W2051258608C2779609443 @default.
• W2051258608 hasConceptScore W2051258608C2780252810 @default.
• W2051258608 hasConceptScore W2051258608C2780372218 @default.
• W2051258608 hasConceptScore W2051258608C2781413609 @default.
• W2051258608 hasConceptScore W2051258608C2781448352 @default.
• W2051258608 hasConceptScore W2051258608C2909675724 @default.
• W2051258608 hasConceptScore W2051258608C2911091166 @default.
• W2051258608 hasConceptScore W2051258608C71924100 @default.
• W2051258608 hasIssue "3" @default.
• W2051258608 hasLocation W20512586081 @default.
• W2051258608 hasLocation W20512586082 @default.
• W2051258608 hasOpenAccess W2051258608 @default.
• W2051258608 hasPrimaryLocation W20512586081 @default.
• W2051258608 hasRelatedWork W1542595140 @default.
• W2051258608 hasRelatedWork W1973796431 @default.
• W2051258608 hasRelatedWork W1981243282 @default.
• W2051258608 hasRelatedWork W1992054903 @default.
• W2051258608 hasRelatedWork W2027497658 @default.
• W2051258608 hasRelatedWork W2030523730 @default.
• W2051258608 hasRelatedWork W2116988530 @default.
• W2051258608 hasRelatedWork W2145971536 @default.
• W2051258608 hasRelatedWork W2220299786 @default.
• W2051258608 hasRelatedWork W2971690211 @default.
• W2051258608 hasVolume "38" @default.
• W2051258608 isParatext "false" @default.

• next